Sagimet Biosciences (SGMT) said Monday it has priced an underwritten offering of about 29.2 million shares at $6.00 each to raise about $175 million to help fund its clinical trial.

Shares soared 43% as intraday trading volume catapulted to over 45.2 million from a daily average of about 516,000.

Veradermics (MANE) said Monday part A of its phase 2/3 trial of VDPHL01 oral pill in males with mild-to-moderate pattern hair loss met all primary and all key secondary endpoints with "high" statistical significance.

Shares surged 32%, with intraday trading volume of over 2.5 million from a daily average of roughly 446,000.

Oruka Therapeutics (ORKA) jumped 16% after the company said Monday almost 64% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.

More than 5.10 million shares traded intraday, compared with a daily average of about 760,000.

Price: 8.36, Change: +2.50, Percent Change: +42.58